Dorsey Wright & Associates boosted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 1.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,139 shares of the medical instruments supplier’s stock after purchasing an additional 318 shares during the period. Dorsey Wright & Associates’ holdings in West Pharmaceutical Services were worth $2,660,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in West Pharmaceutical Services by 0.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,735 shares of the medical instruments supplier’s stock worth $1,015,000 after purchasing an additional 34 shares during the period. Cambridge Investment Research Advisors Inc. raised its stake in West Pharmaceutical Services by 1.6% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 40 shares during the period. Teacher Retirement System of Texas raised its stake in West Pharmaceutical Services by 0.7% during the second quarter. Teacher Retirement System of Texas now owns 5,867 shares of the medical instruments supplier’s stock worth $555,000 after purchasing an additional 40 shares during the period. Private Advisor Group LLC raised its stake in West Pharmaceutical Services by 3.2% during the first quarter. Private Advisor Group LLC now owns 2,899 shares of the medical instruments supplier’s stock worth $232,000 after purchasing an additional 91 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in West Pharmaceutical Services by 2.6% during the first quarter. PNC Financial Services Group Inc. now owns 6,806 shares of the medical instruments supplier’s stock worth $556,000 after purchasing an additional 175 shares during the period. 91.25% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Dorsey Wright & Associates Has $2.66 Million Holdings in West Pharmaceutical Services, Inc. (WST)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/13/dorsey-wright-associates-has-2-66-million-holdings-in-west-pharmaceutical-services-inc-wst.html.

A number of brokerages have commented on WST. BidaskClub downgraded shares of West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $90.00 target price on shares of West Pharmaceutical Services in a research note on Thursday, June 8th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $90.18.

Shares of West Pharmaceutical Services, Inc. (NYSE WST) traded down 0.21% during trading on Wednesday, reaching $91.12. 40,152 shares of the company’s stock were exchanged. The stock has a market capitalization of $6.74 billion, a price-to-earnings ratio of 39.11 and a beta of 1.13. West Pharmaceutical Services, Inc. has a 52 week low of $70.17 and a 52 week high of $99.91. The stock has a 50 day moving average price of $87.51 and a 200-day moving average price of $89.12.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The company had revenue of $397.60 million for the quarter, compared to analysts’ expectations of $406.00 million. During the same period last year, the company earned $0.59 EPS. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. Analysts predict that West Pharmaceutical Services, Inc. will post $2.68 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be issued a dividend of $0.14 per share. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio is presently 22.22%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.